Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06564805

Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata

The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Alopecia Areata Alopecia Hair Diseases Hypotrichosis Skin Diseases Skin and Connective Tissue Diseases

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Universitario "Dr. José Eleuterio González"

Monterrey, Nuevo León, 64460, Mexico

Location status: Recruiting

Location contact

Erika Alba Rojas, MD

CONTACT

[email protected]

+528183891111

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of alopecia areata
  • SALT score of less than 50% extension
  • Has not received any topical or systemic treatment in the last month
  • Signed informed consent

Exclusion criteria

  • Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features
  • Pregnancy or breast-feeding
  • Patients in medications that could cause hair loss as side-effects

Treatment and study plan

Candida Albicans Antigen Injection

Drug

subcutaneous administration of Candida albicans antigen

Primary outcomes

  1. Treatment response

    Time frame: 5 months

    porcentage of hair growth determined by SALT score

Secondary outcomes

  1. Side effects

    Time frame: 5 months

    Side effects associated to the treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Erika Alba-Rojas, MD

CONTACT

[email protected]

+528183891111

Sponsors and collaborators

Lead sponsor

Universidad Autonoma de Nuevo Leon

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Aug 21, 2024
Registry last updated
Aug 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.